How is tirzepatide dosed, and how many units is a dose?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Most often logged by Milligram users
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds Tirzepatide and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    The US tirzepatide labels start at 2.5 mg once weekly: Zepbound goes to 5 mg after 4 weeks and then may be increased in 2.5 mg increments after at least 4 weeks on the current dose, Mounjaro adds 2.5 mg increments after at least 4 weeks if additional glycemic control is needed, and both give a maximum of 15 mg in adults.12

    The guide's example

    2.5 mg of Tirzepatide from a 10 mg vial mixed with 1 mL is 25 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    10 mg30% set up1210 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units5 mg/mL: 2.5 mg is 50 units, 5 mg is 100 units, 7.5 mg is over 1 mL, 10 mg is over 1 mL3.333 mg/mL: 2.5 mg is 75 units, 5 mg is over 1 mL, 7.5 mg is over 1 mL, 10 mg is over 1 mL
    20 mg14% set up1220 mg/mL: 2.5 mg is 12.5 units, 5 mg is 25 units, 7.5 mg is 37.5 units, 10 mg is 50 units10 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units6.667 mg/mL: 2.5 mg is 37.5 units, 5 mg is 75 units, 7.5 mg is over 1 mL, 10 mg is over 1 mL
    30 mg23% set up1230 mg/mL: 2.5 mg is 8.3 units, 5 mg is 16.7 units, 7.5 mg is 25 units, 10 mg is 33.3 units15 mg/mL: 2.5 mg is 16.7 units, 5 mg is 33.3 units, 7.5 mg is 50 units, 10 mg is 66.7 units10 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units
    60 mg9% set up1260 mg/mL: 2.5 mg is 4.2 units, 5 mg is 8.3 units, 7.5 mg is 12.5 units, 10 mg is 16.7 units30 mg/mL: 2.5 mg is 8.3 units, 5 mg is 16.7 units, 7.5 mg is 25 units, 10 mg is 33.3 units20 mg/mL: 2.5 mg is 12.5 units, 5 mg is 25 units, 7.5 mg is 37.5 units, 10 mg is 50 units

    Most often logged by Milligram users: 2.5 mg, 24% logged.12

    Jump to a vial 10 mg 20 mg 30 mg 60 mg

    How many units is a tirzepatide dose?

    Label productStrengthVolume per dose
    Single-dose pen or vial22.5 mg to 15 mg per 0.5 mL0.5 mL
    Multi-dose vial, 10 mg or 20 mg in 2.4 mL14.17 mg/mL or 8.33 mg/mL0.6 mL (2.5 mg or 5 mg)
    Multi-dose vial, 30 mg to 60 mg in 2.4 mL212.5 mg/mL to 25 mg/mL0.6 mL (7.5 mg to 15 mg)

    The labels give each dose as a volume, 0.5 mL or 0.6 mL, measured with a syringe such as a 1 mL syringe, and give no figure in units.2

    Of the people who logged tirzepatide, 30% set up a 10 mg vial, 23% a 30 mg vial, 14% a 20 mg vial and 9% a 60 mg vial, and 12% set up a 10 mg vial with 1 mL of water; these are set-ups in the app, while the label's multi-dose vials are 2.4 mL of solution.1212 The labels give no water type or volume for a powder, and neither does the registry record of a Lilly phase 1 study in healthy participants (NCT03375463, "A Study of Tirzepatide (LY3298176) in Healthy Participants", 52 enrolled across all parts), whose Part A compared a tirzepatide solution with a powder mixed with water.3

    2.5 mg of Tirzepatide from a 10 mg vial mixed with 1 mL is 25 units on a U-100 syringe.

    12% set up 10 mg + 1 mL12

    In an alert on dosing errors with compounded semaglutide, the FDA describes a U-100 (1 milliliter) insulin syringe on which a 5-unit dose is 0.05 milliliter.4

    The calculator is at the top of the page

    What the labels and trials give

    The Zepbound label (to reduce excess body weight and maintain weight reduction in adults with obesity, or overweight with a weight-related comorbid condition, and moderate to severe obstructive sleep apnea in adults with obesity) gives 2.5 mg once weekly for 4 weeks for all indications, then 5 mg once weekly, after which the dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose.2 The Zepbound label gives the abdomen, the thigh or, when given by someone else, the back of the upper arm as subcutaneous sites, rotated with each dose.2

    TrialDose and schedulePeopleLength
    SURMOUNT-1 (Jastreboff and colleagues, 2022)Double blind, subcutaneous once weekly: tirzepatide or placebo; tirzepatide arms started at 2.5 mg and rose 2.5 mg every 4 weeks to 5 mg, 10 mg or 15 mg562539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes72 weeks, 20-week escalation
    SURPASS-1 (Rosenstock and colleagues, 2021)Double blind, once weekly: tirzepatide 5 mg, 10 mg or 15 mg, or placebo7478 adults with type 2 diabetes controlled inadequately by diet and exercise40 weeks

    How tirzepatide is stored

    The Mounjaro label says single-dose pens and vials are stored refrigerated at 2°C to 8°C in the original carton, and if needed can be kept at up to 30°C for a total of 21 days, then thrown away.1 The label says an in-use multi-dose vial is kept at 2°C to 8°C or at up to 30°C, and thrown away after 30 days at room temperature, 30 days after first use or 4 weekly doses.1 For a multi-dose vial not yet in use the label gives 2°C to 8°C, and says it is thrown away after 30 days at room temperature, up to 30°C.1 A letter in Diabetes Obesity Cardiometabolic CARE, "Weighing the Risks and Benefits of Microdosing Tirzepatide Vials", says single-dose vials carry uncertainty about peptide stability and product integrity after repeated entry, and that contamination and bacterial growth are possible.8 For compounded GLP-1 vials holding multiple doses, the FDA generally recommends that multi-dose vials of sterile medications be used within 28 days after first use, for contamination risk; the Mounjaro label gives its own in-use multi-dose vial 30 days after first use.91

    Frequently asked questions

    What if a tirzepatide dose is missed?

    The Zepbound label says to give a missed dose as soon as possible within 4 days (96 hours), and otherwise to skip it.2

    Is there a tirzepatide tablet or pill?

    The US label describes Zepbound as a tirzepatide injection for subcutaneous use, the DailyMed search lists every tirzepatide entry as an injection solution, and no label, regulator page or trial in the sources describes an oral tirzepatide.210

    Can a pen's solution be moved to a syringe or split?

    The Zepbound KwikPen instructions say not to transfer the medicine into a syringe, and to throw the pen away after 4 doses.2 A review in Obesity (Silver Spring), "Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens", reports that labeling says not to transfer the pen's solution to a syringe, use it after four doses or split it into smaller doses, and that microdosing it is not endorsed by the manufacturer or approved by any regulatory agency.11

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. Eli Lilly and Company, via DailyMed (US National Library of Medicine). MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, published 2 Sep 2026). 2026. dailymed.nlm.nih.gov
    2. Eli Lilly and Company, via DailyMed (US National Library of Medicine). ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, published 2 Sep 2026). 2026. dailymed.nlm.nih.gov
    3. ClinicalTrials.gov (US National Library of Medicine). ClinicalTrials.gov NCT03375463 (tirzepatide in healthy participants, solution against lyophilized powder). 2026. clinicaltrials.gov
    4. US Food and Drug Administration. FDA alerts of dosing errors associated with compounded injectable semaglutide products. 2026. fda.gov
    5. New England Journal of Medicine, via PubMed. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), PubMed abstract. 2022. pubmed.ncbi.nlm.nih.gov
    6. ClinicalTrials.gov (US National Library of Medicine). ClinicalTrials.gov NCT04184622 (SURMOUNT-1 registry record). 2026. clinicaltrials.gov
    7. The Lancet, via PubMed. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1), PubMed abstract. 2021. pubmed.ncbi.nlm.nih.gov
    8. Diabetes Obesity Cardiometabolic CARE (American Diabetes Association), via PubMed Central. Weighing the Risks and Benefits of Microdosing Tirzepatide Vials. 2026. pmc.ncbi.nlm.nih.gov
    9. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026). 2026. fda.gov
    10. DailyMed (US National Library of Medicine). DailyMed label search results for the drug name tirzepatide. 2026. dailymed.nlm.nih.gov
    11. Obesity (Silver Spring), via PubMed Central. Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens. 2026. pmc.ncbi.nlm.nih.gov
    12. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted